Paragon 28, Inc., a leading orthopedic foot and ankle company, today announced the completion of a Series B financing. The round was co-led by MVM Partners, a healthcare growth equity investment firm, and Piper Sandler Merchant Banking, a commercial stage growth equity investment business of Piper Sandler Companies. The financing also included participation from an existing Series A investor.

The new financing will support Paragon 28’s ongoing initiatives to develop and launch new products, including the recently FDA cleared APEX 3DTM Total Ankle Replacement System, as well as continued commercial expansion in the US and international markets.

Albert DaCosta, President and CEO of Paragon 28, commented “We are pleased to add this capital to our balance sheet and equally excited about the partnership. The Series B proceeds will enable our team to focus on the best growth opportunities and expand our market position. To close this round on the tenth anniversary of the company is a special moment for our team.”

Kevin Cheng, a partner at MVM, noted “The foot and ankle segment of orthopedics is a relatively new surgical specialty. Paragon 28 is relentlessly focused on improving procedures through an extensive array of novel products that are specifically engineered for lower extremities. We are impressed by the advancements that the Paragon team has made, and we are delighted with the opportunity to support the business through its next phase of growth.”

Tom Schnettler, managing director with Piper Sandler Merchant Banking, added “The team at Paragon 28 has brought tremendous focus and innovation to the foot and ankle segment, an area of the orthopedics market that is growing rapidly and traditionally has been under-served. The company’s innovative solutions and extensive product line benefit surgeons and patients in addressing even the most difficult foot and ankle conditions. We are excited to partner with Paragon 28 and support the company’s mission to innovate and improve foot and ankle surgical outcomes.”

About Paragon 28, Inc.

Paragon 28, Inc. was established in 2010 to address the unmet and under-served needs of the foot and ankle community. From the onset, Paragon 28’s goal has been to re-invent the space of foot and ankle surgery. Through research and innovation, the company creates new and improved solutions to the challenges faced by foot and ankle specialists.

Latest news

Valneva Announces the Pricing of its Initial Public Offering on Nasdaq
May 11, 2021

Saint-Herblain (France), May 6, 2021  – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for […]

Valneva Initiates Phase 3 Clinical Trial for its Inactivated,
Adjuvanted COVID-19 Vaccine Candidate, VLA2001
April 29, 2021

Saint-Herblain (France), April 21, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic […]

Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
April 6, 2021

April 6, 2021 VLA2001 was well tolerated with no safety concerns identified In the high dose group : IgG seroconversion […]

eXmoor pharma secures £12m ($17m) from healthcare investment firm MVM marking milestone towards significant expansion plans
March 16, 2021

eXmoor, the expert cell and gene therapy (CGT) services company (Bristol, England), has announced an initial investment of £12m ($17m) […]

Hologic announces acquisition of Biotheranostics
January 5, 2021

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has agreed to acquire Biotheranostics, Inc., […]

MVM invests in GT Medical
November 23, 2020

GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced it has […]

Valneva announces major COVID-19 vaccine partnership with UK government
September 14, 2020

– UK Government has secured supply of 60 million doses at a cost of €470 million with options over another […]

Valneva confirms participation in UK government COVID-19 vaccine response program
July 20, 2020

Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today confirmed its participation in […]

MDxHealth Announces Growth Investment from MVM Partners
May 18, 2020

Press release Regulated information – Inside information IRVINE, CA, and HERSTAL, BELGIUM – 27 April 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the “Company” […]

MVM leads investment round in SkyCell
May 4, 2020

In April 2020, MVM led the growth investment round in SkyCell, a company that has developed patented temperature-control technology to […]